Spero Therapeutics, Inc., a biopharmaceutical company operating within the Health Care sector, specifically in the Biotechnology industry, has been making strides in addressing the critical issue of multi-drug resistant (MDR) bacterial infections. The company, headquartered in Cambridge, Massachusetts, USA, focuses on the identification, development, and commercialization of novel treatments targeting these resistant infections. Additionally, Spero Therapeutics is known for its innovative technology platform designed to enhance the spectrum and potency of existing antibiotics.
As of June 11, 2026, Spero Therapeutics’ stock was trading at a close price of $2.85 on the Nasdaq, where it is publicly listed. The company’s market capitalization stands at approximately $165.02 million. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $3.22 on July 8, 2025, and a 52-week low of $1.80 on August 19, 2025. The price-to-earnings (P/E) ratio of the company is currently 10.76, reflecting investor sentiment and market expectations regarding its future earnings potential.
Spero Therapeutics went public on the Nasdaq stock exchange on November 2, 2017, marking a significant milestone in its journey to bring innovative solutions to the forefront of antibiotic therapy. The company’s global operations underscore its commitment to addressing the pressing need for effective treatments against MDR bacterial infections, which pose a significant threat to public health worldwide.
The company’s strategic focus on expanding the capabilities of existing antibiotics through its proprietary technology platform positions it as a key player in the biotechnology industry. By enhancing the efficacy of current treatments, Spero Therapeutics aims to provide more robust solutions to combat bacterial infections that have become increasingly resistant to conventional antibiotics.
In summary, Spero Therapeutics, Inc. continues to advance its mission of developing and commercializing novel treatments for MDR bacterial infections, leveraging its technology platform to improve the effectiveness of existing antibiotics. With its operations based in Cambridge, Massachusetts, and its presence on the Nasdaq, the company remains a significant entity in the biotechnology sector, dedicated to addressing one of the most challenging issues in modern healthcare.
